The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe

Current Cardiovascular Risk Reports

Volumn 5, Issue 2, 2011, Pages 174-179

  Bielecka Dabrowa, Agata ^a   Aronow, Wilbert S ^b   Rysz, Jacek ^a   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Eastern Europe; Epidemiology; Hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; THIAZIDE DIURETIC AGENT;

AWARENESS; BLOOD PRESSURE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE COURSE; EARLY INTERVENTION; EASTERN EUROPE; HOSPITALIZATION; HUMAN; HYPERTENSION; INDIVIDUALIZATION; MULTIVARIATE ANALYSIS; PREVALENCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 80052352090     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-010-0152-2     Document Type: Review

References (55)

1. Bruce Goldfarb. ASH Panel Proposes New Hypertension Definition. 2005; 2: 1-7.
2. From the Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke-United States, 1990-1999. JAMA 1999; 282: 724-6.
3. Mancia G, Grassi G. The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis. 2008; 2(1): 5-12.
4. Guidelines Subcommittee, World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
5. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
6. • Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58. These are the current guidelines of European Society of Hypertension, and they recommend new borderline issues on hypertension diagnosis and management.
7. Marques-Vidal P, Tuomilehto J. Hypertens awareness, treatment and control in the community: is the "rule of halves" still valid? J Hum Hypertens 1997; 11: 213-20.
8. Mancia G, Sega R, Milesi C, Cesana S, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-7.
9. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
10. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-6.
11. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-24.
12. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085-91.
13. National High Blood Pressure Education Program Working Group. Arch Intern Med. 1993; 153: 186-208.
14. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
16. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7.
17. Kjeldsen SE, Reims HM, Fagard R and Mancia G. Hypertension. In: Camm AJ, Luscher TF, Serruys PW. The ESC textbook of cardiovascular medicine. P 271-300.
18. Kannel WB. Update on hypertension as a cardiovascular risk factor. In: Manual of Hypertension. Mancia G (ed.). Churchill Livingstone: London 2002; 4-19.
19. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
20. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20: 1307-14.
21. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-62.
22. • Cífková R. Epidemiology and risk of hypertension. Arch Med Sci 2009; 5, 2A: S 199-S 211. This article presents the current data on epidemiology and risk of hypertension, including data from Eastern European countries.
23. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-9.
24. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363-9.
25. Strasser T. Hypertension: the East European experience. Am J Hypertens 1998; 11: 756-8.
26. Zdrojewski T, Bandosz P, Szpakowski Pet al. The prevalence of major risk factors for diseases of the cardiovascular system in Poland. Test results NATPOL PLUS. Kardiol. Pol. 2004; 61(supl. IV): 15-17.
27. Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Prevalence of hypertension and the effectiveness of its treatment in adults in our country. Results of WOBASZ study. Kardiol. Pol. 2005; 63: S614-S619.
28. Kobalava ZhD, Kotovskaia IuV, Starostina EG et al. Problems of a physician-patient interaction and control of arterial hypertension in Russia. Main results of scientific-practical program ARGUS-2. Kardiologiia. 2007; 47(3): 38-47.
29. Cífková R, Skodová Z, Lánská V, et al. Trends in blood pressure levels, prevalence, awareness, treatment and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479-85.
30. • Windak A, Gryglewska B, Tomasik T, Narkiewicz K, Yaphe J, Grodzicki T. Competence of Polish primary-care doctors in the pharmacological treatment of hypertension. J Eval Clin Pract. 2010; 16: 25-30. The authors present the problem with compliance and therapeutic inertia in Poland.
31. • Kobalava ZD, Kotovskaya YV, Villevalde SV, Moiseev VS; ARGUS-2 Study. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. Curr Med Res Opin. 2009; 25: 2229-37. The authors present the data on management of hypertension in Russia.
32. Bajraktari G, Sylejmani X, Thaçi K, Elezi S, Ndrepepa G. The quality of arterial hypertension treatment in cardiology service in Kosovo-a single center study-Original Investigation. Anadolu Kardiyol Derg 2009; 9: 96-101.
33. Kumpusalo E, Parnanen H, Takala J. Treatment situation of hypertensive patients in Finnish primary health care. Blood Press 1997; 1 (Suppl): 35-9.
34. Cuspidi C, Lonati L, Sampieri L, Macca G, Valagussa L, Zaro T, et al. Blood pressure control in a hypertension hospital clinic. J Hypertens 1999; 17: 835-41.
35. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management. Translating clinical trials to practice. Hypertension 2002; 40: 464-9.
36. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.
37. Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16 (Suppl1): S45-S51.
38. Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old. Implications for the treatment decision. Drugs Aging. 1994; 5: 184-191.
39. Verdecchia P, Gentile G, Angeli F, Reboldi G. Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. Pol Arch Med Wewn, 2008; 118: 513-516.
40. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336: 1121-1123.
41. Beckett N, Peters R, Fletcher AE et al. for the HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358: 1887-1898.
42. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005; 91 (Suppl 5): v1-v52.
43. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999; 354: 1751-1756.
44. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
45. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875-886.
46. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175-1180.
47. Fagard RH, van Den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002; 20: 1297-1302.
48. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002; 20: 1461-1464.
49. • Banach M, Kjeldsen SE, Narkiewicz K. Controversies in Hypertension Treatment. Curr Vasc Pharmacol 2010; 8: 731-2. The authors present the current problems in the diagnosis, control, management, treatment, and prevention of hypertension complications in hypertensive patients.
50. • Gaciong Z, Symonides B. Hypertension 2010: What was New for the Cardiologist? Expert Opin Pharmacother 2010; 11: 2579-97. The authors present the current achievements in hypertension management in 2010, including the current guidelines of the European Society of Hypertension.
51. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010; 106: 221-7.
52. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8: 733-41.
53. Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010; 8: 747-52.
54. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009; 5: 3-9.
55. Banach M, Rysz J. Current Problems in Hypertension and Nephrology. Expert Opin Pharmacother 2010; 11: 2575-8.